The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score 9.42 — safe zoneOK
- Earnings-manipulation signal · Beneish M -2.79 — no flag raisedOK
- Earnings quality 94/100 — accruals in line with cashOK
Where the revenue comes from
Fiscal 2025, as WEST PHARMACEUTICAL SERVICES INC reports it. History and quarterly detail are in the app.
- Proprietary Products$2.5B
- Contract-Manufactured Products$582.0M
Leadership changes
From WEST PHARMACEUTICAL SERVICES INC's own filings, the day they're filed.
- Shane Campbell · President · appointmenteff. 2025-05-05
- Cindy Reiss-Clark · Chief Commercial Officer · departureeff. 2025-03-07
- Cindy Reiss-Clark · Chief Commercial Officer · departureeff. 2025-03-07
Latest filings
- 8-K · Company announcement2026-06-01
- 8-K · Company announcement2026-05-11
- 8-K · Company announcement2026-05-05
- 8-K · Company announcement2026-04-23
- 10-Q · Quarterly report2026-04-23
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, every figure source-linked🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask anything about WEST PHARMACEUTICAL SERVICES INC, every answer cited🔒
- The Intelligence Brief — added when WEST PHARMACEUTICAL SERVICES INC's brief passes our SEC-figure check🔒
Every figure links to the filing it came from, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.